CTOs on the Move

Allos Therapeutics

www.allos.com

 
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.allos.com
  • 11080 Circle Point Rd Ste 200
    Westminster, CO USA 80020
  • Phone: 303.426.6262

Executives

Name Title Contact Details

Similar Companies

GVB Biopharma

GVB Biopharma operates two state-of-the-art hemp extraction and white labeling facilities in Central Oregon and Las Vegas, Nevada.

Nutcracker Therapeutics

Nutcracker Therapeutics is an RNA therapeutics company that has combined the power of advanced engineering with high-precision biosynthesis to deploy a complete RNA therapeutics platform. Armed with this high-tech advantage, we have developed a wholly owned pipeline of RNA therapeutic programs and established partnership initiatives with top clinical investigators at several leading institutions across the globe. With our platform`s ability to accelerate the development of life-changing RNA therapeutics, we seek to advance breakthrough RNA therapies at high velocity through all stages of development across a variety of indications. Our technology platform has the potential to significantly reduce costs and cycle times for RNA therapeutic development, with dramatic advantages in capacity scaling and point-of-care delivery over other RNA manufacturing approaches.

Trait Biosciences

Trait Biosciences Inc. is a leading biotechnology research organization providing proprietary technology to enable safer, lower cost, predictable, and superior quality cannabinoid products. With a world-class team of scientists and PhDs from more than 20 countries collaborating in our state-of-the-art Los Alamos laboratory, Trait Biosciences researchers are unlocking new breakthroughs in cannabinoid science. Trait Biosciences offers transformative technologies that create water-soluble cannabinoids, increase cannabinoid production, protect the plants from disease, tailor the production of cannabinoids and that can assure zero THC for hemp.

Tri-Source Pharma

Tri-Source Pharma is a pharmaceutical manufacturer/distributor operating in both the human and animal health care industries.

BioRestorative

BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders: • Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person`s own) cultured mesenchymal stem cells collected from the patient`s bone marrow. We intend that the product will be used for the non-surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. The BRTX-100 production process involves collecting a patient`s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient`s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have received clearance from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain due to degenerative disc disease related to protruding/bulging discs. • Metabolic Program (ThermoStem®): We are developing a cell-based therapy to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (“BAT”). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.